Literature DB >> 18575908

Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.

H S Cheong1, C-I Kang, Y M Wi, K S Ko, D R Chung, N Y Lee, J-H Song, K R Peck.   

Abstract

This study was performed to identify the risk factors for mortality and evaluate the effect of inappropriate initial antimicrobial therapy on the outcomes of patients with community-onset Pseudomonas aeruginosa bacteraemia in an emergency department (ER) setting. All cases with P. aeruginosa bacteraemia occurring within 48 h after ER visit from January 2000 to December 2005 were retrospectively analysed. A total of 106 community-onset P. aeruginosa bacteraemia cases in the ER were included (mean age, 57.61 +/- 14.44 years old; M:F, 58:48). Although P. aeruginosa bacteraemia was diagnosed in the ER, most of the cases of P. aeruginosa bacteraemia were healthcare-associated (88.7%). Malignancy (n = 83, 78.3%) was the most common underlying disorder. Fifty patients (47.2%) were neutropaenic and 56 patients (52.8%) had septic shock. The overall 30-day mortality rate was 26.4% (28/106). In the univariate analysis, underlying malignancy, high Charlson's weighted index of comorbidity (> or = 3), high Pitt bacteraemia score (> or = 4), indwelling central venous catheter and inappropriate initial therapy were significantly associated with 30-day mortality (all P < 0.05). In the multivariate analysis, high Pitt bacteraemia score (OR, 17.03; 95% CI, 4.60-63.15; P < 0.001) and inappropriate initial antimicrobial therapy (OR, 4.29; 95% CI, 1.39-13.24; P = 0.011) were found to be significant risk factors for 30-day mortality. The 30-day mortality rate was significantly higher in the inappropriate therapy group (18/51, 35.3%) than in the appropriate therapy group (10/55, 18.2%) (P = 0.046). This study demonstrated that inappropriate initial antimicrobial therapy was significantly associated with unfavourable outcomes in patients with community-onset P. aeruginosa bacteraemia. As P. aeruginosa bacteraemia can be a fatal infection, even when community-onset, inappropriate antimicrobial therapy should be avoided in suspected cases of P. aeruginosa bacteraemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575908     DOI: 10.1007/s10096-008-0568-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

Review 1.  Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations.

Authors:  R A Balk
Journal:  Crit Care Clin       Date:  2000-04       Impact factor: 3.598

2.  Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.

Authors:  Cheol-In Kang; Sung-Han Kim; Hong-Bin Kim; Sang-Won Park; Young-Ju Choe; Myoung-Don Oh; Eui-Chong Kim; Kang-Won Choe
Journal:  Clin Infect Dis       Date:  2003-08-23       Impact factor: 9.079

3.  Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.

Authors:  Scott T Micek; Ann E Lloyd; David J Ritchie; Richard M Reichley; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Pseudomonas aeruginosa bacteremia in children: analysis of trends in prevalence, antibiotic resistance and prognostic factors.

Authors:  G Grisaru-Soen; L Lerner-Geva; N Keller; H Berger; J H Passwell; A Barzilai
Journal:  Pediatr Infect Dis J       Date:  2000-10       Impact factor: 2.129

5.  Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes.

Authors:  F Vidal; J Mensa; M Almela; J A Martínez; F Marco; C Casals; J M Gatell; E Soriano; M T Jimenez de Anta
Journal:  Arch Intern Med       Date:  1996-10-14

Review 6.  Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary.

Authors:  J W Chow; V L Yu
Journal:  Int J Antimicrob Agents       Date:  1999-01       Impact factor: 5.283

7.  The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit.

Authors:  R Zaragoza; A Artero; J J Camarena; S Sancho; R González; J M Nogueira
Journal:  Clin Microbiol Infect       Date:  2003-05       Impact factor: 8.067

8.  Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity.

Authors:  Olivier Lesens; Cédric Methlin; Yves Hansmann; Véronique Remy; Martin Martinot; Colm Bergin; Pierre Meyer; Daniel Christmann
Journal:  Infect Control Hosp Epidemiol       Date:  2003-12       Impact factor: 3.254

9.  Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.

Authors:  Sheryl A Zelenitsky; Godfrey K M Harding; Siyao Sun; Kiran Ubhi; Robert E Ariano
Journal:  J Antimicrob Chemother       Date:  2003-09-01       Impact factor: 5.790

10.  Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis.

Authors:  Francisco Arancibia; Torsten T Bauer; Santiago Ewig; Josep Mensa; Julia Gonzalez; Michael S Niederman; Antoni Torres
Journal:  Arch Intern Med       Date:  2002-09-09
View more
  15 in total

1.  Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation.

Authors:  Désirée Caselli; Simone Cesaro; Ottavio Ziino; Giulio Zanazzo; Rosaria Manicone; Susanna Livadiotti; Monica Cellini; Stefano Frenos; Giuseppe M Milano; Barbara Cappelli; Maria Licciardello; Chiara Beretta; Maurizio Aricò; Elio Castagnola
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

2.  Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.

Authors:  E-J Joo; C-I Kang; Y E Ha; S Y Park; S-J Kang; Y M Wi; N Y Lee; D R Chung; K R Peck; J-H Song
Journal:  Infection       Date:  2011-05-19       Impact factor: 3.553

3.  Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.

Authors:  Laura Morata; Nazaret Cobos-Trigueros; José A Martínez; Alex Soriano; Manel Almela; Francesc Marco; Holguer Sterzik; Raquel Núñez; Cristina Hernández; José Mensa
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

4.  Infectious Disease Consults of Pseudomonas aeruginosa Bloodstream Infection and Impact on Health Outcomes.

Authors:  Swetha Ramanathan; Fritzie S Albarillo; Margaret A Fitzpatrick; Katie J Suda; Linda Poggensee; Amanda Vivo; Martin E Evans; Makoto Jones; Nasia Safdar; Chris Pfeiffer; Bridget Smith; Geneva Wilson; Charlesnika T Evans
Journal:  Open Forum Infect Dis       Date:  2022-09-09       Impact factor: 4.423

5.  Pseudomonas aeruginosa Community-Onset Bloodstream Infections: Characterization, Diagnostic Predictors, and Predictive Score Development-Results from the PRO-BAC Cohort.

Authors:  Pedro María Martínez Pérez-Crespo; Álvaro Rojas; Joaquín Felipe Lanz-García; Pilar Retamar-Gentil; José María Reguera-Iglesias; Olalla Lima-Rodríguez; Alfonso Del Arco Jiménez; Jonathan Fernández Suárez; Alfredo Jover-Saenz; Josune Goikoetxea Aguirre; Eva León Jiménez; María Luisa Cantón-Bulnes; Pilar Ortega Lafont; Carlos Armiñanzas Castillo; Juan Sevilla Blanco; Jordi Cuquet Pedragosa; Lucía Boix-Palop; Berta Becerril Carral; Alberto Bahamonde-Carrasco; Teresa Marrodan Ciordia; Clara Natera Kindelán; Isabel María Reche Molina; Carmen Herrero Rodríguez; Inés Pérez Camacho; David Vinuesa García; Fátima Galán-Sánchez; Alejandro Smithson Amat; Esperanza Merino de Lucas; Antonio Sánchez-Porto; Marcos Guzmán García; Inmaculada López-Hernández; Jesús Rodríguez-Baño; Luis Eduardo López-Cortés
Journal:  Antibiotics (Basel)       Date:  2022-05-24

6.  Antibiotic resistance rates for Pseudomonas aeruginosa clinical respiratory and bloodstream isolates among the Veterans Affairs Healthcare System from 2009 to 2013.

Authors:  Haley J Appaneal; Aisling R Caffrey; Lan Jiang; David Dosa; Leonard A Mermel; Kerry L LaPlante
Journal:  Diagn Microbiol Infect Dis       Date:  2017-12-06       Impact factor: 2.803

7.  Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.

Authors:  Ioannis A Bliziotis; Nicola Petrosillo; Argyris Michalopoulos; George Samonis; Matthew E Falagas
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

8.  The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia.

Authors:  H G Ternavasio-de la Vega; F Castaño-Romero; S Ragozzino; R Sánchez González; M P Vaquero-Herrero; M Siller-Ruiz; G Spalter-Glicberg; C Ramírez-Baum; S Rodríguez-Rodríguez; J E García-Sánchez; I García-García; M Marcos
Journal:  Epidemiol Infect       Date:  2018-09-03       Impact factor: 4.434

9.  Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.

Authors:  Youn Jeong Kim; Yoon Hee Jun; Yang Ree Kim; Kang Gyun Park; Yeon Joon Park; Ji Young Kang; Sang Il Kim
Journal:  BMC Infect Dis       Date:  2014-03-24       Impact factor: 3.090

10.  Pseudomonas aeruginosa bacteremia in patients with liver cirrhosis: a comparison with bacteremia caused by Enterobacteriaceae.

Authors:  Ji Hwan Bang; Younghee Jung; Shinhye Cheon; Chung Jong Kim; Kyung Ho Song; Pyeong Gyun Choe; Wan Beom Park; Eu Suk Kim; Sang Won Park; Hong Bin Kim; Myoung-don Oh; Hyo-Suk Lee; Nam Joong Kim
Journal:  BMC Infect Dis       Date:  2013-07-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.